Tempus GEMINI-NSCLC study - WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East.

Considering the hypothesis that central hubs are associated with increased lethality, identifying key hub targets within central networks could lead to the development of
novel drugs with improved efficacy in advanced metastatic solid tumors.

(Click to view trial detail)